Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
Phase of Trial: Phase III
Latest Information Update: 08 Apr 2016
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Thromboembolism; Venous thromboembolism
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 08 Apr 2016 Results (n=22) published in the Journal of Thrombosis and Haemostasis.
- 24 Mar 2016 Status changed from recruiting to discontinued due to slow recruitment as reported by ClinicalTrials.gov.